{"id":"deferiprone-dfp","safety":{"commonSideEffects":[{"rate":null,"effect":"Agranulocytosis"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Gastrointestinal disturbances (nausea, abdominal pain)"},{"rate":null,"effect":"Arthralgia"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Deferiprone is a bidentate chelating agent that forms stable complexes with ferric iron (Fe³⁺), facilitating its urinary excretion. By reducing labile iron pools and preventing iron-catalyzed free radical formation, it mitigates oxidative damage to organs such as the heart and liver in patients with chronic iron overload.","oneSentence":"Deferiprone is an iron chelator that binds and removes excess iron from the body, reducing iron-induced tissue damage.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:32:16.953Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Iron overload in patients with thalassemia major"},{"name":"Iron overload in other chronic transfusion-dependent anemias"}]},"trialDetails":[{"nctId":"NCT02655315","phase":"PHASE2","title":"Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2016-02-09","conditions":"Parkinson Disease","enrollment":372},{"nctId":"NCT03293069","phase":"PHASE2, PHASE3","title":"Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2019-01-30","conditions":"Amyotrophic Lateral Sclerosis","enrollment":372},{"nctId":"NCT02728843","phase":"PHASE2","title":"Study of Parkinson's Early Stage With Deferiprone","status":"COMPLETED","sponsor":"ApoPharma","startDate":"2016-10-12","conditions":"Parkinson's Disease","enrollment":140},{"nctId":"NCT01825512","phase":"PHASE3","title":"Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients","status":"COMPLETED","sponsor":"Consorzio per Valutazioni Biologiche e Farmacologiche","startDate":"2014-03-17","conditions":"Chronic Iron Overload","enrollment":435},{"nctId":"NCT02174848","phase":"PHASE3","title":"Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration","status":"COMPLETED","sponsor":"ApoPharma","startDate":"2014-06","conditions":"Pantothenate Kinase-Associated Neurodegeneration","enrollment":68},{"nctId":"NCT01741532","phase":"PHASE3","title":"Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)","status":"COMPLETED","sponsor":"ApoPharma","startDate":"2012-12-13","conditions":"Pantothenate Kinase-Associated Neurodegeneration","enrollment":89},{"nctId":"NCT01740713","phase":"PHASE2","title":"Pharmacokinetic Study of Deferiprone in Paediatric Patients","status":"COMPLETED","sponsor":"Consorzio per Valutazioni Biologiche e Farmacologiche","startDate":"2012-12","conditions":"Chronic Iron Overload","enrollment":23},{"nctId":"NCT02456558","phase":"PHASE1","title":"Evaluation of the Safety, Efficacy, and Pharmacokinetics of Intravenous Deferiprone in HIV-Positive Subjects","status":"COMPLETED","sponsor":"ApoPharma","startDate":"2015-06","conditions":"Asymptomatic HIV Infection","enrollment":30},{"nctId":"NCT02173951","phase":"PHASE2, PHASE3","title":"An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2014-07","conditions":"Beta Thalassemia Major","enrollment":64},{"nctId":"NCT01989455","phase":"PHASE1","title":"A Blinded, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single Doses of Intravenous Deferiprone in Healthy Volunteers","status":"COMPLETED","sponsor":"ApoPharma","startDate":"2013-11","conditions":"Healthy Volunteers","enrollment":64},{"nctId":"NCT01860703","phase":"PHASE4","title":"Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects","status":"COMPLETED","sponsor":"ApoPharma","startDate":"2012-11","conditions":"Prolonged QTc Interval","enrollment":50},{"nctId":"NCT01767103","phase":"PHASE4","title":"An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild and Moderate Hepatic Insufficiency and Healthy Volunteers","status":"COMPLETED","sponsor":"ApoPharma","startDate":"2013-01","conditions":"Hepatic Impairment","enrollment":21},{"nctId":"NCT01770652","phase":"PHASE4","title":"An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild, Moderate, Severe, or No Renal Impairment","status":"COMPLETED","sponsor":"ApoPharma","startDate":"2013-01","conditions":"Renal Impairment","enrollment":32},{"nctId":"NCT02198508","phase":"NA","title":"Clinical Trial of Deferasirox Combination Treatment With Deferiprone In Thalassaemia Patients","status":"COMPLETED","sponsor":"China Medical University Hospital","startDate":"2007-07","conditions":"Beta-thalassemia Major","enrollment":13},{"nctId":"NCT02083575","phase":"PHASE2, PHASE3","title":"Role of Vitamin C to Augment Iron Chelation With DFP or DFX","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2014-04","conditions":"Vitamin c, Thalassemia Major, Iron Chelation","enrollment":50},{"nctId":"NCT01838291","phase":"","title":"Active Drug Surveillance Program of Ferriprox Use","status":"COMPLETED","sponsor":"ApoPharma","startDate":"2010-06","conditions":"Transfusional Iron Overload","enrollment":294},{"nctId":"NCT01511848","phase":"PHASE2, PHASE3","title":"Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2012-02","conditions":"Beta-thalassemia Major, Sickle Cell Disease, Iron Hemosiderosis","enrollment":60},{"nctId":"NCT00733811","phase":"PHASE4","title":"Efficacy Study of the Use of Sequential DFP-DFO Versus DFP","status":"COMPLETED","sponsor":"Azienda Ospedaliera V. Cervello","startDate":"2000-09","conditions":"Beta-Thalassemia, Thalassemia Major","enrollment":213}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":237,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DFP (Apotex, Canada)"],"phase":"marketed","status":"active","brandName":"Deferiprone (DFP)","genericName":"Deferiprone (DFP)","companyName":"Azienda Ospedaliera V. Cervello","companyId":"azienda-ospedaliera-v-cervello","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Deferiprone is an iron chelator that binds and removes excess iron from the body, reducing iron-induced tissue damage. Used for Iron overload in patients with thalassemia major, Iron overload in other chronic transfusion-dependent anemias.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}